VILNIUS, LITHUANIA / ACCESSWIRE / June 30, 2020 / Ziticity, Lithuanian last-mile delivery service has closed a €2.2 million seed equity investment round. The round was led by NordicNinja VC (FIN) in participation with Superhero Capital VC (FIN), Practica Capital (LT), StartupWiseGuys (EE) and Superangel VC (EE), to fund Ziticity's expansion in Europe.

Founded in 2017, Ziticity empowers local businesses owners to compete with large Silicon Valley tech companies dominance by providing the platform for affordable same-day deliveries. With an on-demand solution, local e-shops and restaurants can optimize and distribute deliveries in real-time without usual distribution centres and paying high commission fees to shipping companies or food delivery platforms.

According to Ziticity's data, 60% of last-mile deliveries are within a five-kilometre radius from pickup to the drop-off location. Short delivery distances widen the possibility for couriers to use any means of transportation including cars, bicycles, e-scooters, etc.

Since launch, Ziticity has been a success in France and the Baltics, used by over 2700 companies like Telia, Tele2, Pizza Hut, and Euroapotecha pharmacies' network. Thanks to urban batching logic, the reached average delivery time is 42 minutes and couriers are able to complete 4-6 deliveries per hour. This keeps prices affordable to the shopper, while couriers are able to earn +15% more per hour than in competing platforms.

The company has been steadily growing 22% month over month ever since the launch with a sharp 44% revenue increase during COVID-19.

"Local e-commerce cannot compete on product price with Amazon and Alibaba. To have a fighting chance with global tech giants that are building monopolies in e-commerce and restaurant delivery space, we have been able to build a direct service for local merchants to compete locally." – says Laimonas Noreika, the founder and CEO of ZITICITY who built the company out of personal frustration.

"The delivery industry is expected to increase dramatically and 2.1 billion people are expected to buy goods online by 2021. On top of that, current global pandemic changes people's behavior and habits like how they buy, sell and eat at an unprecedented rate of change. We believe that ZITICITY's solution is a kind of silver lining approach for the industry and end-users which need to adjust for new normal. " – says Tomosaku Sohara, Managing Partner at NordicNinja VC.

After successful piloting, Ziticity is preparing for entering several countries in Europe.

-ENDS-

Ziticity
Ziticity helps local merchants to compete with Amazon and Alibaba dominance by providing affordable same-day deliveries. ZITICITY connects their e-commerce stores with urban hubs, optimizes routes and distributes heavy-batched deliveries to on-demand couriers for maximum efficiency. zwww.ziticity.com

NordicNinja VC
NordicNinja VC is a 100 million euro deeptech fund focused on the Nordics & the Baltics. For more information, visit www.nordicninja.vc

CONTACTS

Ziticity

Laimonas Noreka
CEO, Ziticity
+370 695 05823, laimonas.noreika@ziticity.com

Claes Mikko Nilsen
Investment Director, NordicNinja VC
+358 504 913001, claes.mikko@nordicninja.vc

SOURCE: Ziticity

ReleaseID: 595632

Strong Monthly Visitor Growth at Artnet News

Revenue Increase in 2019 Despite Generally Weak Auction Market

BERLIN, GERMANY and NEW YORK, NY / ACCESSWIRE / June 30, 2020 / Berlin-based Artnet AG, the leading provider of art market data and online-only fine art auctions, projects an accelerated digitalization and a growing acceptance of online transactions in the art market. "The current economic downturn is accelerating the digital transformation of the market which we have advanced since our founding three decades ago," said Jacob Pabst, CEO of Artnet AG. "The crucial roles that the Internet and e-commerce currently play will lead to fundamental changes in consumer behavior and leverage Artnet's strengths as the market leader in the online art market."

In May, sales at Artnet Auctions doubled year-over-year to $4 million, setting a new monthly record. Artnet Auctions, founded in 2008, is Artnet's online-only transaction platform for fine art auctions. Given the widespread lockdown, Artnet Auctions became one of the few remaining options for buying and selling works of art as traditional brick-and-mortar auctions were canceled due to the pandemic.

As in the auction business, the digital dissemination of information, which Artnet has promoted for many years, gathers momentum. The news platform Artnet News has become the primary source of information for the art market, generating more traffic than all other art publications combined. Artnet News has established itself as the leading source of exclusive information and news in the art world, thereby strengthening the entire Artnet brand. Last year, the average number of visitors to Artnet increased by 20% to 3.6 million per month overall. In the current financial year, 4.8 million visitors came to Artnet per month between January and the end of May.

The Gallery Network enables member galleries to promote artists and artworks to Artnet's global online audience. A sound e-commerce strategy is essential for galleries that are currently dependent on the Internet due to the lockdown. "We are seeing increased interest from galleries wanting to take advantage of online opportunities," said Artnet CEO Pabst.

The Price Database, the most comprehensive online archive for auction results and the core of Artnet, provides price transparency, orientation and reliable information to the art market ever since its founding in 1989. The Price Database, whose wealth of data is also the basis of Artnet News' reporting, remains an indispensable research tool for art market participants with currently some 14 million illustrated auction results.

In the 2019 financial year, Artnet grew total revenue by 1% to $21.9 million year-over-year, despite the weak international art market. According to the Artnet Price Database, the total annual auction sales value for fine art declined globally by 11% to $13.1 billion, also affecting Artnet. Artnet's overall revenue growth resulted from the high demand for advertising space on Artnet News. Advertising revenue overall increased by 20% to $5.4 million in 2019, as compared to the previous year. For the first time, advertising became Artnet's second-largest revenue source after Price Database subscriptions. However, declining revenues in the Gallery Network and Artnet Auctions segments slowed the overall growth. Accordingly, the operating income of $197k for 2019 was lower than expected.

In the first quarter of 2020, Artnet's total revenue decreased slightly by 2% year-on-year to $5.14 million due to the onset of the economic downturn and the market panic in March. As stated in the 2019 annual report, Artnet expects a slight revenue decline in the 2020 financial year due to reduced advertisers' budgets in light of the global recession. Overall, Artnet predicts revenues in a range of $20.0 million to $21.0 million for 2020. "We are tackling the crisis from a position of strength," said Artnet CEO Jacob Pabst. "As a leading online provider of information, analysis and auctions for fine art, Artnet is in an ideal position to benefit from the growing importance of e-commerce in the art market."

The 2019 annual report is available at http://www.artnet.com/investor-relations/annual-reports

The report for the first quarter of 2020 is available at http://www.artnet.com/investor-relations/quarterly-reports

For further information, please contact: press@artnet.com

About Artnet
Artnet is the leading resource for buying, selling, and researching art online. Founded in 1989, Artnet's suite of industry-leading products has revolutionized the way people collect art today. The Price Database contains approximately 14 million auction results from 1,800 auction houses dating back to 1985, providing an unparalleled level of transparency to the art market. The Gallery Network platform connects leading galleries with collectors from around the world, offering the most comprehensive overview of artworks for sale. Artnet Auctions was the first dedicated online marketplace for fine art, providing a seamless and efficient collecting experience for both buyers and sellers. Artnet News covers the events, trends, and people shaping the global art market with up-to-the-minute analysis and expert commentary.

Artnet AG is listed in the Prime Standard of the Frankfurt Stock Exchange, the segment with the highest transparency standards.

SOURCE: artnet AG via EQS Newswire

ReleaseID: 595721

RADNOR, PA / ACCESSWIRE / June 29, 2020 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Enphase Energy, Inc. (NASDAQ:ENPH) ("Enphase") on behalf of those who purchased or otherwise acquired Enphase common stock between February 26, 2019 and June 17, 2020, inclusive (the "Class Period").

Important Deadline: Investors who purchased or otherwise acquired Enphase common stock during the Class Period may, no later than August 17, 2020, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please click https://www.ktmc.com/enphase-energy-inc-class-action?utm_source=PR&utm_medium=link&utm_campaign=enphase.

According to the complaint, Enphase is a global energy technology company that delivers smart, easy-to-use solutions that manage solar generation, storage and communication on one intelligent platform. Enphase asserts that it revolutionized the solar industry with its microinverter technology, and that it produces a fully integrated solar-plus-storage solution.

The Class Period commences on February 26, 2019, when Enphase issued a press release on a Form 8-K with the SEC in which it announced Enphase's financial results for the fourth quarter and year-ended 2018. In the press release, Enphase stated that for the fourth quarter of 2018 it had revenue of $92.3 million, an increase of 18% sequentially and an increase of 16% year-over-year. The press release further stated that Enphase's non-GAAP gross margin was 30.7%, a decrease of 210 basis points from 32.8% in the third quarter. For the full year ended December 31, 2018, Enphase reported revenue of $316.159 million, with gross margins of 29.9%, up from $286.166 million and 19.6% for the year ended December 31, 2017.

The complaint alleges that, on June 17, 2020, analyst Prescience Point Capital Management ("Prescience Point") published a report in which it wrote that "[a]t least $205.3m of ENPH's reported FY19 US revenue is fabricated, and a significant portion of its international revenue is fabricated as well." The report continued: "[m]ost, if not all, of the 2,080 Bps expansion in ENPH's gross margin since Q2'17 is also fabricated," and called on Enphase's accountant, Deloitte, to "launch an in-depth investigation of EPNH's accounting practices." Prescience Point further called on "[r]egulatory and law enforcement agencies with subpoena power [to] launch a full investigation of the Company, its accounting, its disclosures and trading by insiders."

Following this news, Enphase's stock price fell by approximately 26% in one day, from its June 16, 2020 close of $52.76 per share to a June 17, 2020 close of $39.04 per share.

The complaint alleges that, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) its revenues, both U.S. and international, were inflated; (2) Enphase engaged in improper deferred revenue accounting practices; (3) Enphase's reported basis point expansion in gross margins was overstated; and (4) as a result of the foregoing, the defendants' public statements were materially false and misleading at all relevant times.

If you wish to discuss this securities fraud class action lawsuit or have any questions concerning this notice or your rights or interests with respect to this litigation, please contact Kessler Topaz Meltzer & Check (James Maro, Jr., Esq. or Adrienne Bell, Esq.) at (844) 877-9500 (toll free) or (610) 667-7706, or via e-mail at info@ktmc.com.

Enphase investors may, no later than August 17, 2020, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 877-9500 (toll free)
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 595681

Conference Call Scheduled for Tuesday, June 30th at 11:30 AM EDT

NORTHVALE, NJ / ACCESSWIRE / June 29, 2020 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2020 ("Fiscal 2020").

Consolidated revenues for Fiscal 2020 were $18.0 million, an increase of $10.4 million or approximately 137% from the comparable period of the prior fiscal year. The increase in revenues was largely attributed to revenues from products launched during the 2020 Fiscal Year, generic immediate release Adderall®, generic extended release Adderall®, and generic Dantrolene Capsules, as well as strong growth in revenues relating to the sales of Isradipine capsules.

Conference Call Information

Elite's management will host a conference call to discuss the year-end 2020 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.

Date:

June 30, 2020

Time:

11:30 AM EDT

Dial-in numbers:

1-800-346-7359 (domestic)
1-973-528-0008 (international)

Conference number:

98840

Questions:

Financial questions by 7:00 AM EDT on Tuesday, June 30, 2020
Email to: dianne@elitepharma.com

Audio Replay:

https://elite.irpass.com/events_presentations

The financial statements can be viewed for Elite's Fiscal Year 2020 on Form 10-K here.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry. Elite owns generic products which have been licensed to TAGI Pharma, Glenmark Pharmaceuticals, Inc., USA., and Lannett Company, Inc. Elite currently has eleven approved generic products, three generic products filed with the FDA, one approved generic products pending manufacturing site transfer, and an NDA filed for SequestOx™. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com. The information found on Elite's website is not incorporated by reference into this press release and is included for reference purposes only.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, Elite's ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of SequestOx™ by the FDA, and the actions the FDA require of Elite in order to obtain approval of the NDA. These forward-looking statements are not guarantees of future action or performance. These risks and other factors, including, without limitation, Elite's ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews, and approvals by the Food and Drug Administration and other regulatory authorities and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com

SOURCE: Elite Pharmaceuticals, Inc.

ReleaseID: 595623

NEW YORK, NY / ACCESSWIRE / June 29, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Mylan N.V. (NASDAQ:MYL)
Class Period: February 16, 2016 – May 7, 2019
Lead Plaintiff Deadline: August 25, 2020

During the class period, Mylan N.V. allegedly made materially false and/or misleading statements and/or failed to disclose that: 1) the Food and Drug Administration's investigation into the Company's manufacturing plant in Morgantown, West Virginia was the result of whistleblower allegations, and not, as Mylan insinuated, the result of a "regular" inspection; and 2) defendants knew, or were reckless in not knowing that, as a result of Mylan's continued efforts to remain uncooperative with the Food and Drug Administration, the Morgantown plant would continue to incur substantial setbacks.

Learn about your recoverable losses in MYL: http://www.kleinstocklaw.com/pslra-1/mylan-n-v-loss-submission-form-2?id=7647&from=1

Ideanomics, Inc. (NASDAQ:IDEX)
Class Period: March 20, 2020 – June 25, 2020
Lead Plaintiff Deadline: August 27, 2020

According to the complaint, Ideanomics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Ideanomics' Mobile Energy Global Division in Qingdao, China (the "MEG Center") was not "a one million square foot EV expo center" as the Company had stated in press releases; (ii) the Company had been using doctored or altered photographs of the purported MEG Center in Qingdao; (iii) the Company's electric vehicle business in China was not performing nearly as strongly as Ideanomics had represented; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in IDEX: http://www.kleinstocklaw.com/pslra-1/ideanomics-inc-loss-submission-form?id=7647&from=1

Brookdale Senior Living Inc. (NYSE:BKD)
Class Period: August 10, 2016 – April 29, 2020
Lead Plaintiff Deadline: August 24, 2020

The BKD lawsuit alleges that throughout the class period, Brookdale Senior Living Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Brookdale's financial performance was sustained by, among other things, the Company's purposeful understaffing of its senior living communities; (ii) the foregoing conduct subjected Brookdale to an increased risk of litigation and, once revealed, was foreseeably likely to have a material negative impact on the Company's financial results and reputation; (iii) as a result, the Company's financial results were unsustainable; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in BKD: http://www.kleinstocklaw.com/pslra-1/brookdale-senior-living-inc-loss-submission-form?id=7647&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 595676

WINNIPEG, MB / ACCESSWIRE / June 29, 2020 / Bird River Resources Inc. (CSE:BDR) ("BDR" or the "Company") announces that due to circumstances created by the Covid-19 pandemic, it will not be filing its 3rd quarter interim financial statements and related management discussion and analysis by their scheduled due date of June 29, 2020 as required under section 4.4 (b) and section 5.1(1) of National Instrument 51-102 – Continuous Disclosure Obligations ("NI 51-102").

As required by Manitoba Blanket Order 52-502 Temporary Exemption from Certain Corporate Finance Requirements (Manitoba Blanket Order 52-502), Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Finance Requirements (OSC Instrument 51-502) and BC Instrument 51-515 Temporary Exemption from Certain Corporate Finance Requirements (BC Instrument 51-515), the Company discloses the following:

the Company's management and other insiders will be subject to a trading black-out that reflects the principles in Section 9 of National Policy 11-207 – Failure-to-File Cease Trade Orders until its 3rd quarter interim financial statements and related management discussion and analysis are filed, which it expects to file on or before August 12, 2020; and
there have been no undisclosed material developments in the business of the Company following the date of the Company's 1st quarter interim financial statements and management discussion and analysis, filed to the Company's SEDAR profile on June 11, 2020.

About Bird River Resources Inc.

Established in 1958, Bird River Resources Inc. is a Winnipeg, Manitoba based diversified resource company which holds producing oil and gas wells in the Huxley Alberta area through its wholly owned subsidiary High Point Oil Inc. BDR also holds minority interests in nine producing oil and gas wells in southwestern Manitoba. Additional information on the Company is available at https://birdriverresources.com and at sedar.com.

For further information, contact:

Jon Bridgman, CEO
Bird River Resources Inc.
Tel: 1-877-587-0777 and jonbirdriver@gmail.com

This news release is for information purposes only and no statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities and may contain forward looking statements that are based upon current expectations or beliefs as well as a number of assumptions about future events and words such as may, should, could, will, expect, anticipate, estimate, believe, intend, project should not be taken out of context.

NEITHER THE CSE NOR ITS MARKET REGULATOR (AS THAT TERM IS DEFINED IN THE POLICIES OF THE CSE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS PRESS RELEASE.

SOURCE: Bird River Resources Inc.

ReleaseID: 595675

Meeting scheduled to reconvene July 22, 2020 at 10:30 AM Eastern Time

ENGLEWOOD, CO / ACCESSWIRE / June 29, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2020 Annual Meeting of Stockholders in order to permit stockholders additional time within which to vote. The adjourned meeting will be held at 10:30 AM Eastern Time on Wednesday, July 22, 2020. The adjourned meeting will also be a "virtual" meeting of stockholders. The record date for the annual meeting is May 6, 2020. A stockholder may use one of the following simple methods to vote:

Vote by Internet at www.proxyvote.com until 11:59 PM Eastern Time on July 21, 2020 using the 16-digit control number appearing on the proxy card.

Vote by telephone by calling the toll-free telephone number 1-800-690-6903 until 11:59 PM Eastern Time on July 21, 2020 using their 16-digit control number appearing on the proxy card.

Vote by mail by marking, dating and signing the proxy card, and returning it in the postage-paid envelope provided to Broadridge Financial Solutions, Inc.

Vote at the virtual Annual Meeting by joining the meeting at www.virtualshareholdermeeting.com/VIVE2020 using the 16-digit control number included on the proxy card.

About Viveve

Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates CMRF technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. In the United States, the Viveve System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in more than 50 countries.

Viveve continues to advance its clinical development program in SUI and is conducting a short-term feasibility study under an Investigational Testing Application approved by the Canadian Ministry of Health. The feasibility study is a single-blind, three-arm study to compare Viveve's CMRF treatment and a cryogen-only sham to an inert sham treatment in order to capture short-term safety and effectiveness data on use of the Viveve System for the improvement of SUI in women. Subject enrollment in the study was completed in March 2020. Results of the SUI feasibility study are targeted for readout in late summer of 2020. If positive, the feasibility study results could support our initiation of our pivotal PURSUIT trial pending FDA's approval of Viveve's IDE application.

For more information visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

Important Information

In connection with the solicitation of proxies, on May 18, 2020, Viveve filed a definitive proxy statement with the Securities and Exchange Commission ("SEC") in connection with its 2020 Annual Meeting. STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE DEFINITIVE PROXY MATERIALS AND ANY OTHER RELEVANT SOLICITATION MATERIALS FILED BY VIVEVE WITH THE SEC BEFORE MAKING ANY VOTING OR INVESTMENT DECISION BECAUSE THESE DOCUMENTS CONTAIN IMPORTANT INFORMATION. Viveve's proxy statement and any other materials filed by Viveve with the SEC can be obtained free of charge at the SEC's web site at www.sec.gov. Viveve's proxy statement, notice of annual meeting, and annual report to stockholders are available free of charge on Viveve's website at http://www.viveve.com. The contents of the websites referenced above are not deemed to be incorporated by reference into the proxy statement.

Viveve is a registered trademark of Viveve, Inc.

Investor Relations contacts:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

Media contact:
Bill Berry
Berry & Company Public Relations
(212) 253-8881
bberry@berrypr.com

SOURCE: Viveve Medical, Inc.

ReleaseID: 595668

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESSWIRE / June 29, 2020 / Commerce Resources Corp. (TSXV:CCE)(FSE:D7H0) (the "Company" or "Commerce") announces that, further to its News Release of June 26, 2020, whereby it announced the closing of a non-brokered private placement (the "Offering") of 6,686,939 units (each, a "Unit") at a price of $0.18 per Unit for gross proceeds of $1,203,649.02, it wishes to disclose the updated amount of finders' fees paid in connection with the Offering to cash finder's fees of $53,076.80 and 290,067 Finder's Warrants.

None of the securities sold in connection with the Offering will be registered under the United States Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Commerce Resources Corp.

Commerce Resources Corp. is an exploration and development company with a particular focus on deposits of rare metals and rare earth elements. The Company is focused on the development of its Ashram Rare Earth Element Deposit in Quebec and the Upper Fir Tantalum-Niobium Deposit in British Columbia.

For more information, please visit the corporate website at www.commerceresources.com or email info@commerceresources.com.

On Behalf of the Board of Directors
COMMERCE RESOURCES CORP.

"Chris Grove"

Chris Grove
President and Director
Tel: 604.484.2700
Email: cgrove@commerceresources.com
Web: http://www.commerceresources.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Commerce Resources Corp.

ReleaseID: 595669

NEW YORK, NY / ACCESSWIRE / June 29, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Ryder System, Inc. (NYSE:R)
Class Period: July 23, 2015 – February 13, 2020
Lead Plaintiff Deadline: July 20, 2020

Throughout the class period, Ryder System, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Ryder's financial results were inflated as a result of the Company's practice of overstating the residual values of the vehicles in its fleet; (2) there was no reasonable basis to believe that Ryder would sell its used vehicles for the amounts that it had assigned to them; (3) Ryder's residual values for its fleet of vehicles exceeded the expected future values that would be realized upon the sale of those vehicles; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in R: http://www.kleinstocklaw.com/pslra-1/ryder-system-inc-loss-submission-form?id=7646&from=1

Forescout Technologies, Inc. (NASDAQ:FSCT)
Class Period: February 6, 2020 – May 15, 2020
Lead Plaintiff Deadline: August 10, 2020

The complaint alleges Forescout Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Forescout was experiencing a significant and disproportionate decline in its financial performance; (2) the foregoing was reasonably likely to have a material negative impact on Forescout's planned acquisition by Advent International Corp.; and (3) as a result of the foregoing, defendants' statements about its business and operations were materially false and misleading at all relevant times.

Learn about your recoverable losses in FSCT: http://www.kleinstocklaw.com/pslra-1/forescout-technologies-inc-loss-submission-form-2?id=7646&from=1

Casper Sleep Inc. (NYSE:CSPR)
in or traceable to the Company's public offering conducted on or around February 7, 2020.
Lead Plaintiff Deadline: August 18, 2020

The CSPR lawsuit alleges that Casper Sleep Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Casper's profit margins were actually declining, rather than growing; (2) Casper was changing an important distribution partner, costing it 130 basis points of gross margin in the first quarter of 2020 alone; (3) Casper was holding a glut of old and outdated mattress inventory that it was selling at steeply discounted clearance prices, further impairing the Company's profitability; (4) Casper was suffering accelerating losses, further placing its ability to achieve positive cash flows and profitability out of reach; (5) Casper's core operations were not profitable, but were causing the Company to suffer over $40 million in negative cash flows during the first quarter of 2020 alone and doubling its quarterly net loss year over year; (6) as a result of the foregoing, Casper's ability to achieve profitability, implement its growth initiatives, and expand internationally had been misrepresented in the documents issued in connection with Casper's initial public offering, as the Company needed to shutter its European operations, halt all international expansion, jettison over one fifth of its global corporate workforce, and significantly curtail new store openings in order to avoid an imminent cash and liquidity crisis, let alone achieve positive operating cash flows; and (7) as a result of the foregoing, Casper's revenue growth rate was not sustainable and had not positioned the Company to achieve profitability.

Learn about your recoverable losses in CSPR: http://www.kleinstocklaw.com/pslra-1/casper-sleep-inc-loss-submission-form?id=7646&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 595667

LOS ANGELES, CA / ACCESSWIRE / June 29, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against PlayAGS, Inc. ("PlayAGS" or "the Company") (NYSE:AGS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between August 2, 2018 and August 7, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before August 24, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. PlayAGS was experiencing severe challenges in its Oklahoma business. These challenges were likely to negatively impact the Company's recurring revenue. The Company was also experiencing trouble with its interactive business segment, such as delays in securing regulatory approvals. These challenges were likely to result in the Company recording a goodwill impairment. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about PlayAGS, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 595658